stockrow
Saturday 7 November 2026
Export IMTX’s income statement to Excel — free account
Immatics N.V.
IMTX Healthcare Biotechnology
Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024.
- Revenue
- +97.7%
- EPS
- +19.7%
- Free cash flow
- −44.4%
Quarter to June 2026, against a year earlier
6.34
0.16
+2.59%
Follow IMTX
Alert me
Immatics N.V. (IMTX) P/E ratio
Immatics N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 167× (June 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 39.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 11.4× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 167×
Ten-year median
0.0×
Current reading's percentile
68
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ODTX Odyssey Therapeutics, Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| SVRA Savara Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IMTX Immatics N.V. | n/m |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)